S-100β does not predict outcome after mild traumatic brain injury

Area of Science:

• Neuroscience
• Traumatology
• Biomarker Research

Background:

• Mild traumatic brain injury (MTBI) can lead to prolonged post-concussive symptoms and delayed return-to-work or school (RTWS).
• Identifying reliable predictors of long-term outcomes is crucial for managing MTBI patients.
• S-100β, a marker of central nervous system damage, has been investigated for its prognostic potential.

Purpose of the Study:

• To evaluate the predictive utility of serum S-100β levels for mid- and long-term outcomes following MTBI.
• To determine if pre-injury factors, injury characteristics, and S-100β levels can predict outcomes at 3, 6, and 12 months post-injury, including RTWS.

Main Methods:

• A cohort of 150 MTBI patients without severe injury complications was recruited.
• Admission S-100β levels and baseline concussion symptoms were measured.
• Outcomes, including symptom frequency and RTWS, were assessed at multiple follow-up points (3-10 days, 3, 6, and 12 months) using statistical models.

Main Results:

• Serum S-100β levels showed no significant association with post-concussive symptomatology at any follow-up interval.
• No correlation was found between S-100β levels and the ability to return-to-work or school at 12 months post-injury.
• Eleven percent of MTBI patients were unable to RTWS at the 12-month follow-up.

Conclusions:

• Serum S-100β is not a reliable predictor of prolonged post-concussive syndrome after MTBI.
• S-100β levels do not appear to be associated with delayed return-to-work or school in MTBI patients.
• Further research may be needed to identify other reliable biomarkers for MTBI outcomes.